Molecular markers and therapeutic targets in ductal carcinoma in situ

Microscopy Research and Technique

Volumn 59, Issue 1, 2002, Pages 3-11

  Boland, Gary P ^a   Knox, W Fiona ^a   Bundred, Nigel J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; DCIS; Models; Receptors

Indexed keywords

CELL DEATH; CELL PROLIFERATION; DIAGNOSIS; DISEASES;

BREAST CANCER; BREAST CONSERVATION SURGERY; CHEMOPREVENTION; CONDITION; DUCTAL CARCINOMA IN SITU; MAMMOGRAPHIC; MOLECULAR MARKER; NEOPLASTIC LESIONS; RECEPTOR; THERAPEUTIC TARGETS;

MOLECULAR BIOLOGY;

ANTIESTROGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RALOXIFENE; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SCREENING; CARCINOMA IN SITU; CELL CYCLE; CHEMOPROPHYLAXIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALIA;

EID: 0036786311     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10172     Document Type: Article

References (60)

1. Allan DJ, Howell A, Roberts SA, Williams GT, Watson RJ, Coyne JD, Clarke RB, Laidlaw IJ, Potten CS. 1992. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 167:25-32.
2. Allred DC, Mohsin SK, Fuqua SA. 2001. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47-61.
3. Anderson E, Clarke RB, Howell A. 1998. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 3:23-35.
4. Baselga J, Averbuch SD. 2000. ZD1839 ('Iressa') as an anticancer agent. Drugs 60(Suppl 1):33-40.
5. Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch, CA, Duval C, Pilotti S, van de Vijver MJ. 2001. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 84:539-544.
6. Chan KC, Knox WF, Gandhi A, Slamon DJ, Potten CS, Bundred NJ. 2001. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 88:412-418.
7. Charriaut-Marlangue C, Ben Ari Y. 1995. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 7:61-64.
8. Clarke RB, Howell A, Potten CS, Anderson E. 1997. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987-4991.
9. Coffey Jr RJ, Meise KS, Matsui Y, Hogan BL, Dempsey PJ, Halter SA. 1994. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7, 12-dimethylbenzanthracene. Cancer Res 54:1678-1683.
10. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281:2189-2197.
11. Dairkee SH, Deng G, Stampfer MR, Waldman FM, Smith HS. 1995. Selective cell culture of primary breast carcinoma. Cancer Res 55:2516-2519.
12. Dankort DL, Muller WJ. 2000. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 19:1038-1044.
13. Ernster VL, Barclay J. 1997. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 151-156.
14. Ferguson DJ, Anderson TJ. 1981. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 44:177-181.
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. 1998a. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
16. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. 1998b. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452.
17. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. 1999. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 86:429-438.
18. Fox SB, Harris AL. 1997. The epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2:131-141.
19. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ. 1998. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast. Br J Cancer 78:788-794.
20. Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ. 2000. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res 60:4284-4288.
21. George WD, Houghton J, Cuzick J, Forbes J. 2000. Radiotherapy and Tamoxifen following complete local excision (CLE) in the management of ductal carcinoma in situ (DCIS): preliminary results from the UK DCIS trial [Abstract]. Proc Am Soc Clin Oncol 19[A270].
22. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. 1995. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21:1465-1468.
23. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C. 2000. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19:1020-1027.
24. Harn HJ, Shen KL, Yueh KC, Ho LI, Yu JC, Chiu SC, Lee WH. 1997. Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyltransferase-mediated dUTP-FITC nick end labelling (TUNEL). Histopathology 31:534-539.
25. Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD, Bundred NJ. 1997. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst 89:1059-1065.
26. Hwang D, Scollard D, Byrne J, Levine E. 1998. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455-460.
27. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M, Takayama S, Reed JC. 1999. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6:29-40.
28. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ. 2001. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7:429-434.
29. Lagios MD. 1993. Heterogeneity of ductal carcinoma in situ of the Breast. J. Cell Biochem Suppl 17G:49-52.
30. Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E. 1995. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 136:164-171.
31. Megha T, Ferrari F, Arcuri F, Lalinga AV, Lazzi S, Cardone C, Cevenini G, Leoncini L, Tosi P. 2000. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast. Oncol Rep 7:473-478.
32. Merritt AJ, Potten CS, Watson AJ, Loh DY, Nakayama K, Nakayama K, Hickman JA. 1995. Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 108(Pt 6):2261-2271.
33. Mills RR, Bobrow LG, Barnes DM. 1996. Immunohistochemical evaluation of biological markers in mammary carcinoma in situ: correlation with morhological features and recently proposed schemes for histological classification. Breast 5:113-122.
34. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. 1999. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59:5647-5650.
35. Mundle S, Iftikhar A, Shetty V, Dameron S, Wright-Quinones V, Marcus B, Loew J, Gregory S, Raza A. 1994. Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem 42:1533-1537.
36. Oh YL, Choi JS, Song SY, Ko YH, Han BK, Nam SJ, Yang JH. 2001. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 51:94-99.
37. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. 1995. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low-grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197-1200.
38. Parton M, Dowsett M, Smith I. 2001. Studies of apoptosis in breast cancer. Br Med J 322:1528-1532.
39. Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A. 1988. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163-170.
40. Rao JK, Letada P, Haverstick DM, Herman MM, Savory J. 1998. Modifications to the in situ TUNEL method for detection of apoptosis in paraffin-embedded tissue sections. Ann Clin Lab Sci 28:131-137.
41. Rohan TE, Hartwick W, Miller AB, Kandel RA. 1998. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 90:1262-1269.
42. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. 2000. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275:22583-22589.
43. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. 1995. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789.
44. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP. 1999. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811-1815.
45. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
46. Siziopikou KP, Schnitt SJ. 2000. MIB-1 proliferation index in ductal carcinoma in situ of the breast: relationship to the expression of the apoptosis-regulating proteins bcl-2 and p53. Breast J 6:400-406.
47. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. 2000. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
48. Sullivan RP, Mortimer G, Muircheartaigh IO. 1993. Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression. Ir J Med Sci 162:343-347.
49. Tsuda H, Hirohashi S. 1998. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the noninvasive and invasive portions. Pathol Int 48:518-525.
50. Tsuji S, Tsujii M, Kawano S, Hori M. 2001. Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis. J Exp Clin Cancer Res 20:117-129.
51. Tsujii M, Kawano S, DuBois RN. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340.
52. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
53. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ III. 1999. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987-990.
54. Vakkala M, Paakko P, Soini Y. 1999. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer 81:592-599.
55. Waldman FM, De Vries S, Chew KL, Moore DH, Kerlikowske K, Ljung BM. 2000. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 92:313-320.
56. Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ. 1995. The development of a functionally relevant cell culture model of progressive human breast cancer. Semin Cancer Biol 6:175-184.
57. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. 1995. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1:1257-1260.
58. Zaugg K, Bodis S. 2000. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast? Radiother Oncol 55:95-99.
59. Zhou Q, Wulfkuhle J, Ouatas T, Fukushima P, Stetler-Stevenson M, Miller FR, Steeg PS. 2000. Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. Breast Cancer Res Treat 59:27-39.
60. Zhou Q, Hopp T, Fuqua SA, Steeg PS. 2001. Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment. Cancer Lett 162:3-17.